Biogen reported an 11% year-over-year increase in third quarter revenue to $2.8 billion as its growth portfolio delivered 49% growth, highlighting a return to growth. The company raised its full-year 2026 Non-GAAP diluted EPS guidance range to reflect ongoing business strength and favorable Apellis integration.